Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olmesartan Medoxomil vs Losartan in Elderly Patients with Essential Hypertension
NCT00751751Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2003
- Primary completion
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olmesartan in essential hypertension (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in mean sitting diastolic blood pressure at 12 weeks. Started Jun 2003; status: completed.
02
Drugs
olmesartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00751751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00751751.